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and Nicola Low1Abstract
Background: Pelvic inflammatory disease (PID) results from the ascending spread of microorganisms from the
vagina and endocervix to the upper genital tract. PID can lead to infertility, ectopic pregnancy and chronic pelvic
pain. The timing of development of PID after the sexually transmitted bacterial infection Chlamydia trachomatis
(chlamydia) might affect the impact of screening interventions, but is currently unknown. This study investigates
three hypothetical processes for the timing of progression: at the start, at the end, or throughout the duration of
chlamydia infection.
Methods: We develop a compartmental model that describes the trial structure of a published randomised
controlled trial (RCT) and allows each of the three processes to be examined using the same model structure. The
RCT estimated the effect of a single chlamydia screening test on the cumulative incidence of PID up to one year
later. The fraction of chlamydia infected women who progress to PID is obtained for each hypothetical process by
the maximum likelihood method using the results of the RCT.
Results: The predicted cumulative incidence of PID cases from all causes after one year depends on the fraction of
chlamydia infected women that progresses to PID and on the type of progression. Progression at a constant rate
from a chlamydia infection to PID or at the end of the infection was compatible with the findings of the RCT. The
corresponding estimated fraction of chlamydia infected women that develops PID is 10% (95% confidence interval
7-13%) in both processes.
Conclusions: The findings of this study suggest that clinical PID can occur throughout the course of a chlamydia
infection, which will leave a window of opportunity for screening to prevent PID.
Keywords: Chlamydia infection, Pelvic inflammatory disease, Mathematical model, Compartmental model,
Randomised controlled trialsBackground
Pelvic inflammatory disease (PID) is a clinical syndrome
resulting from the ascending spread of microorganisms
from the vagina and endocervix to the endometrium, fal-
lopian tubes, and/or contiguous structures [1]. Damage
to the fallopian tubes following PID is a predisposing
factor for ectopic pregnancy and infertility [2]. Chla-
mydia trachomatis (chlamydia) has been found in* Correspondence: herzog.sereina@gmail.com
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reproduction in any medium, provided the orapproximately 30% of all PID cases [2,3] and is the most
common bacterial sexually transmitted infection in many
developed countries [4]. Chlamydia infection is usually
asymptomatic in women, but can be treated with anti-
biotics when diagnosed [5]. The estimated mean dur-
ation of untreated asymptomatic infection is more than
one year in women [6,7].
Early detection and treatment of chlamydia through
screening has been proposed as a strategy to prevent
PID and subsequent reproductive tract morbidity in
sexually active young women [8]. Three randomised
controlled trials have investigated the efficacy of a singleLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Figure 1 Schematic overview of the model framework. The
model has a susceptible-infected-susceptible (SIS) framework and
allows three hypothetical processes for the timing of progression
from chlamydia to PID to be investigated. A woman can become
infected at rate λ (force of infection), can clear her infection naturally
(rate r), or can be effectively screened and treated (rate α). Numbers
indicate when during the chlamydia infection progression to PID
could happen: 1) immediate progression, 2) constant progression,
and 3) progression at the end of infection. For all three types of
progression a certain fraction f of chlamydia-infected women will
develop PID. For the constant progression model a woman moves
from being infected without PID (I1) to being infected with PID (I2)
at rate γ, which is set to γ ¼ f1f r. For immediate progression and
the progression at the end of infection we set γ ¼ 0 and I ¼ I1 þ I2.
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diagnosed PID with a follow-up period of one year in
young women [9-11]. Uptake of screening ranged from
64 to 100% and all three trials found a reduction in the
incidence of PID from any cause in the intervention
group compared to the control group.
It is important to understand when in the course of in-
fection PID occurs and when screening and treatment
should take place to maximise the potential of chlamydia
screening to prevent PID, but this is currently unknown.
The natural history of untreated chlamydia in humans
cannot be directly observed for ethical and logistical rea-
sons and randomised controlled trials do not provide
this information because the time from the start of in-
fection is unknown. It has been suggested that treatment
is needed soon after infection, based on observations
from an animal model [12]. Pal et al. isolated the C. tra-
chomatis mouse pneumonitis biovar from the upper
genital tract 24 hours after vaginal inoculation in mice
[12].
Mathematical modelling studies are a valuable tool for
investigating hypothetical processes of chlamydia trans-
mission and ascending infection. Amongst the few math-
ematical modelling studies with explicit descriptions of
progression from chlamydia infection to PID, it has been
proposed that PID develops in the first half of a chla-
mydia infection, in the second half, or can occur at any
time during a chlamydia infection [13]. The objectives of
this study were: to investigate how differences in the
timing of progression from chlamydia infection to PID
affect the outcome of a chlamydia screening interven-
tion; and to estimate the fraction of chlamydia infections
that progresses to PID, using a mathematical model to
simulate the results of a published randomised con-
trolled trial.
Methods
Data
We used data from the Prevention Of Pelvic Infection
(POPI) randomised controlled trial of chlamydia screen-
ing, which provides information about C. trachomatis
infection status at baseline in both the intervention and
the control groups and about incident clinically diag-
nosed PID up to one year later [11,14]. In brief, the
study enrolled about 2500 sexually active women aged
16 to 24 years from colleges and universities in London.
All women provided self-collected vaginal swabs at en-
rolment and were randomised to immediate testing for
chlamydia infection and treatment if positive (interven-
tion group), or the collected swabs were stored and
tested after one year (control group). The prevalence of
chlamydia infection was 5.4% (68/1254) in the interven-
tion group and 5.9% (75/1265) in the control group, i.e.
overall 5.7% (143/2519). About 22.2% (527/2377) of thewomen in both groups reported being tested independ-
ently for chlamydia during the follow-up period. The in-
cidence of clinically diagnosed PID (by self-report,
mostly backed up by examination of medical records)
after one year was 1.3% (15/1191, 95% CI 0.7 to 2.1%) in
the intervention group and 1.9% (23/1186, 95% CI 1.2 to
2.9%) in the control group. The incidence rates of PID
in women with chlamydia infection at baseline were
1.6% (1/63) in the intervention group and 9.5% (7/74) in
the control group. Amongst women in the control group
who developed PID, 30.0% (7/23) were chlamydia posi-
tive at baseline.Model
We developed a compartmental model that describes
the trial structure using a Susceptible-Infected-
Susceptible (SIS) framework (Figure 1). We assume a
closed population of susceptible (S) women who can be-
come infected (I) at constant rate λ, i.e., the force of in-
fection, and clear the infection naturally at rate r. The
infection is separated into two stages so that we can dis-
tinguish between infected women without PID (I1) and
with PID (I2). The transition from the first to the second
stage happens at the progression rate γ and allows us to
investigate different possibilities for the timing of pro-
gression in the same model. During follow-up a woman
can receive a test and is successfully treated at rate α,
which incorporates the percentage of women (c) who
reported being tested for chlamydia during the follow-up
period and the proportion with treatment failure (δ).
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tial equations:
dS tð Þ
dt
¼ λS tð Þ þ r þ αð Þ I1 tð Þ þ I2 tð Þð Þ
dI1 tð Þ
dt
¼ λS tð Þ  r þ αþ γð ÞI1 tð Þ
dI2 tð Þ
dt
¼ γI1 tð Þ  r þ αð ÞI2 tð Þ
The force of infection λ is assumed to be constant
over time because the study population is small com-
pared to the population in which the study took place so
changes in prevalence within the study population are
unlikely to affect the overall chlamydia prevalence. The
force of infection λ is calibrated so that the steady state
prevalence in the model is equal to the prevalence p at
baseline in the absence of the trial (α= 0). We assume
the infection duration to be exponentially distributed [6]
with a mean duration of 1/r. This takes into account the
fact that that some women clear the infection rapidly
whereas others can remain infected for substantially
longer time periods [7].
At model initiation we simulate the conditions in the
two arms in the trial. In the control group, a percentage
of women is infected, reflecting the observed baseline
prevalence. In the intervention group all women have
received treatment but a small percentage remains
infected owing to treatment failure (see Additional file 1
for more details).
Types of progression
We explored three hypothetical processes for the timing
of progression from endocervical C. trachomatis infec-
tion to PID (Figure 1). For each type of progression it is
assumed that, of all women infected, a certain fraction f
will develop PID in the absence of an intervention. The
first possibility is that PID develops at the start of a chla-
mydia infection (immediate progression); the incidence
of PID depends on the force of infection and the num-
ber of susceptible women (fλS), so we set γ= 0 and I =
I1 + I2. The second possibility is that PID can develop at
a constant rate throughout the course of a chlamydia in-
fection (constant progression); the incidence of PID
depends on the progression rate γ and the number of
women in the infected compartment without PID (γI1).
The progression rate is defined as γ ¼ f1f r and the
mean duration of the infection is consistent with the
other two types of progression. Finally, progression to
PID could happen at the end of a chlamydia infection
just before natural clearance (progression at the end). In
this situation, PID incidence depends on the clearancerate and the number of infected women (frI), where γ= 0
and I = I1 + I2. In the absence of the trial (α= 0), the inci-
dence rates of PID are the same for all three types of
progression. The cumulative incidence of PID cases
caused by C. trachomatis is tracked for both groups and
is set to zero at model initiation (Additional file 1).
Proportion of PID cases caused by C. trachomatis
The observed numbers of PID cases in the intervention
and control group are presumed to be a mixture of
PID cases caused by C. trachomatis and by other micro-
organisms. We assume that a certain proportion x of
PID cases in the control group is caused by chlamydia
and that the amount caused by other microorganisms is
the same in both groups. In the simulated trial it is
assumed that the intervention only reduces the inci-
dence of chlamydial PID.
The model estimates the cumulative incidence of chla-
mydial PID for the intervention group (gI) and for the
control group (gC). We get the overall cumulative inci-
dence of PID cases in the intervention group (eI) and in
the control group (eC) by using the proportion of PID
cases caused by chlamydia (x), as follows:
eC ¼ gCx
eI ¼ gI þ eC  gCð Þ
where (eC-gC) is the contribution of PID caused by other
microorganisms. Note that to obtain the overall cumula-
tive incidence for PID cases it is required that x > 0.
Analysis
We compared the overall cumulative incidence of PID
cases predicted by the model for each type of progres-
sion in intervention and control groups using the base-
line values (Table 1). First, we examined the predicted
cumulative incidences of chlamydial PID after one year
when varying the fraction of chlamydia infection pro-
gressing to PID from 0 to 100%. Second, we used the
maximum likelihood method to obtain the best fit esti-
mate (and standard error) for the fraction progressing
for each type of progression, using the observed cumula-
tive incidences of PID cases in the trial. Third, we esti-
mated the best fit (and standard error) for the fraction
progressing to PID amongst women who were chla-
mydia positive at baseline, assuming that all PID cases
were caused by C. trachomatis. The best fits for the
models for the three types of progression were com-
pared based on Akaike’s Information Criterion (AIC)
(Additional file 1) [15]. Fourth, for each type of progres-
sion we used baseline values and the obtained maximum
likelihood estimators to determine the time point since
start of infection until half of the expected PID cases oc-
curred (see Additional file 1 for more details).
Table 1 Parameter values describing the natural history of chlamydia infection, PID development and the screening
intervention
Parameters Baseline
values
Explanation Sensitivity analysis Source
Distribution Parameters
Model parameters
λ Force of infection (per day), calculated using*
1/r 365 Mean duration of infection (days) [6,16] N(μ,σ2) μ=365 σ2=752 Consensus
p 5.7% Prevalence at baseline [11] Bin(n,p) n=2519 p ¼ 1432519 [11]
α Effective testing rate (per day), calculated using†
c 22.2% Coverage of testing uptake (per year) [11] Bin(n,p) n=2377 p ¼ 5272377 [11]
δ 8.0% Treatment failure [17] U(a,b) a=0% b=50% Consensus
f estimated Fraction of women becoming infected
with chlamydia who will develop PID
Input parameter
x 30.0% Proportion of PID cases due to chlamydia
in control group [11]
Bin(n,p) n=23 p ¼ 723 [11]
*In the absence of the tria (α=0), to observe chlamydia prevalence p at steady state: λ ¼ p1p r.
†Reported uptake of chlamydia testing c during the follow-up period (outside of the trial) is reduced by the proportion with treatment failure δ, which results in
the effective testing rate α ¼ ln 1 1δð Þcð Þ365 per day [18].
N(μ,σ2), normal distribution (mean, variance); Bin(n,p), binomial distribution (size, probability); U(a,b), uniform distribution (minimum, maximum).
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A univariable sensitivity analysis was done for all model
parameters and the proportion of PID cases caused by
chlamydia. The parameters were varied within the 95%
confidence interval using the distributions in Table 1.
We obtained the maximum likelihood estimates for the
fraction of women progressing to PID. Second, we did a
multivariable sensitivity analysis by sampling each model
parameter and the proportion of PID cases caused by
chlamydia 1000 times from the distributions in Table 1.
The maximum likelihood estimates for the fraction of
women progressing to PID were determined and the
quantiles (0.025 and 0.975) were obtained as 95% cred-
ibility intervals.
Third, we explored the effect of varying the mean time
between start of infection and when progression to PID
becomes possible. We do this in a model framework
similar to the constant progression scenario. An add-
itional parameter ~f
 
is needed to specify the fraction of
women who develop PID at the time point when PID
becomes possible. This differs from the fraction f in that
~f refers only to the women who remain infected at the
time point at which progression to PID becomes pos-
sible. We did not fit this model with the additional un-
known parameter to the trial data as we have only two
data points.We derived maximum likelihood estimates
for the fraction ~f
 
for a fixed mean time between start
of infection and progression to PID and report the cor-
responding fraction f (see Additional file 1 for more
details).Analytical results were derived in Mathematica and
numerical solutions were obtained in R [19,20]. Code
files can be obtained from the authors on request.Results
The predicted cumulative incidence of PID cases from
chlamydia infection after one year depends on the frac-
tion of chlamydia infected women who progress to PID
and on the type of progression (Figure 2). In the inter-
vention groups, the immediate progression scenario
results in the highest cumulative incidence of PID, pro-
gression at the end the lowest, with intermediate values
for the constant progression scenario (Figure 2A). In the
control groups the predicted cumulative incidence of
PID is similar for all three types of progression
(Figure 2B).
In the immediate progression scenario, the predicted
cumulative incidence of PID in the intervention and
control groups is very similar; for any value of the frac-
tion progressing to PID, women in both groups develop
PID immediately after infection so testing and treating
does not prevent any PID cases (Figure 2A, 2B). If the
fraction progressing to PID is 100%, all women who be-
come infected will progress to PID and the predicted cu-
mulative incidence of PID after one year is similar to the
baseline prevalence of chlamydia, because the mean dur-
ation of infection was assumed to be one year.
For scenarios of constant progression to PID or pro-
gression at the end of chlamydia infection, the predicted
cumulative incidences of PID are similar if the fraction
progressing to PID is low because the formulae
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Figure 2 Predicted cumulative incidence of chlamydial PID for the three types of timing of progression. Panel A, results for intervention
group; panel B, results for control group. Immediate progression (dashed line); constant progression (solid line); progression at the end (dashed-
dotted line). The fraction progressing from chlamydia to PID is varied from 0-100% using baseline values for all other model parameters.
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approaches zero (Figure 2A). For both of these scenarios,
the incidence of PID depends on the number of infected
women. The scenario with progression at the end always
has a lower cumulative incidence than the other two,
even when the fraction progressing to PID is 100%, be-
cause some of the infected women will have been effect-
ively tested and treated before they clear the infection
naturally, which is when they are at risk of developing
PID.
Table 2 shows the maximum likelihood estimator
(MLE) and the corresponding 95% CI for the estimated
fraction of chlamydia infected women who progress to
PID, using the observed cumulative incidences from the
trial. The corresponding cumulative incidences of PID
cases in the intervention and control groups shown are
the best fitting values. For all types of progression to
PID, the best fitting values for the fraction of women
progressing to PID are between 8 and 10%. The AIC
values are similar so the estimated fractions progressing
to PID with all three types of progression are compatible
with the data. Similar results were obtained considering
only the point estimates of the cumulative incidence ofTable 2 Estimated fraction progressing from chlamydia infect
Progression to PID Fraction
progressing,
% (95% CI)*
Cumulative in
Control grou
Data
Results from RCT 1.9 (1.2 to 2.
Model
Immediate progression 8.3 (5.7 to 11.0) 1.6 (1.1 to 2.
Constant progression 9.9 (6.8 to 13.0) 1.7 (1.2 to 2.
Progression at the end 10.0 (6.8 to 13.1) 1.7 (1.2 to 2.
*The 95% CI is obtained by using the corresponding standard error and assuming a
†Cumulative incidence of PID after one year caused by chlamydia and other microo
{ Akaike’s information criterion values describe fit of model.
PID, pelvic inflammatory disease; RCT, randomised controlled trial; CI, confidence inPID cases of women who were chlamydia positive at
baseline (results not shown).
In the scenario of constant progression to PID, with a
constant daily risk of developing PID, it takes 228 days
until half of the expected PID cases are observed and for
the progression at the end it takes 253 days, using the
MLE in Table 2 (see Additional file 1 Figure A1). In the
immediate progression scenario, it takes 0 days which is
an intuitive consequence of progression without a delay.
Sensitivity analysis
In the univariable analysis the proportion of PID cases
due to chlamydia in the control group is the most influ-
ential parameter affecting the best fit for the fraction
progressing to PID (Figure 3). Within the range of values
sampled, the fraction progressing to PID varies from 4
to 19% (Figure 3A). The cumulative incidences of PID
cases caused by chlamydia and other microorganisms
after one year (Figure 3B-D) are also influenced for the
scenarios of constant progression or progression at the
end of infection but only marginally for immediate pro-
gression. Varying the duration of chlamydia infection or
the baseline prevalence influences the force of infectionion to PID, using baseline values
cidence of PID after one year, % (95% CI)† Akaike’s
Information
Criterion{
p Intervention group
9) 1.3 (0.7 to 2.1)
1) 1.6 (1.1 to 2.1) 13.3
3) 1.5 (1.0 to 1.9) 12.1
3) 1.5 (1.0 to 1.9) 12.1
normal distribution.
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progressing or the cumulative incidence of all-cause
PID. Changing the percentage with treatment failure or
the uptake of testing during follow up has marginal in-
fluence (results not shown). In the multivariable sensitiv-
ity analysis the means over all parameter sets for the
fraction progressing to PID were similar to those in the
baseline analysis (see Additional file 1 Figure A2). In the
additional model framework the corresponding best fit-
ting values for the fraction of infected women develop-
ing PID (f ) were in the same range as the main three
types of progression (see Additional file 1 Figure A3).Discussion and conclusion
This study used a mathematical model to simulate the
results of a randomised controlled trial of a chlamydia
screening intervention. The predicted cumulative inci-
dence of PID was lower in the intervention than the
control group if progression to PID occurred at a con-
stant rate or at the end of chlamydia infection. If pro-
gression to PID occurs immediately after chlamydia
infection, screening and treatment do not reduce the cu-
mulative incidence of PID. The model estimates, for
constant progression and progression at the end, that10% (95% CI 7-13%) of chlamydia infections progress to
PID.
A strength of this study was the use of a dynamic
mathematical model to investigate the timing of progres-
sion from chlamydia infection to PID. There were, how-
ever, several simplifying assumptions. First, it is not
biologically plausible for chlamydia to ascend in the
genital tract either immediately after endocervical infec-
tion or just before natural clearance. These extreme
situations were chosen to represent progression early
and late in the course of chlamydia infection. Other
plausible possibilities about the timing of progression,
e.g. assuming a woman has to be infected for a certain
time period before being at a constant daily risk of
developing PID, were not investigated because we did
not have enough data to fit models with more than one
unknown parameter. Second, we counted the number of
PID episodes rather than the number of women devel-
oping PID. The model structure assumed that PID could
happen repeatedly in the same woman but that a history
of PID did not influence the course of chlamydia infec-
tion, susceptibility to chlamydia or future progression to
PID. These assumptions might not be true but, since
both the trial follow-up period and baseline value for the
mean duration of chlamydia infection were one year,
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repeated chlamydia infections or PID episodes in the
model. Third, it was assumed that antibiotic treatment
was specific to C. trachomatis, which is not the case.
Azithromycin is also active against Mycoplasma genita-
lium but a causal association with PID is still debated so
it was not possible to estimate the potential effect of
treatment on other microorganisms [2,21]. Finally, we
considered a closed population; this was a reasonable as-
sumption because very few women in the trial were lost
to follow-up.
The use of empirical data from a randomised con-
trolled trial was also an advantage. The Prevention of
Pelvic Infection study is the only trial with data about
the baseline prevalence of chlamydia in the control
group, which allowed us to investigate the incidence of
PID amongst untreated women. There are also limita-
tions to the trial. Although discussed previously [11], we
restate limitations as they apply to our study here. First,
the point estimates of PID incidence were rather impre-
cise, owing to the lower than expected incidence of PID
in the trial [11]. The relative reduction in PID incidence
in the Prevention of Pelvic Infection study was consist-
ent with, but smaller than in the other two randomised
trials [9,10], probably because of a lower risk of meth-
odological bias; another possibility is the high testing up-
take during the follow-up period in both groups [3,11].
When using the maximum likelihood method to esti-
mate the fraction progressing to PID, the best fit values
for the cumulative PID incidence rates in the control
and intervention groups were closer than observed in
data. The value for the control group was, nevertheless,
higher than for the intervention group for the model as-
suming a constant rate of progression. Second, we only
used the values for the 12-month incidence of PID to fit
the model, rather than individual dates of PID diagnosis.
These dates were collected retrospectively, by self-report
backed by medical records, but were limited to the date
when the participant presented to a healthcare facility
and was diagnosed with PID, and were not accurate
enough to construct a survival curve. Third, only symp-
tomatic PID cases were observed so the cumulative inci-
dence of PID cases could have been underestimated.
This would lead to an underestimation of the fraction of
women becoming infected with chlamydia who will de-
velop PID.
There are very few mathematical modelling studies
that consider explicitly how the timing of progression to
PID might affect the outcome of chlamydia screening
interventions [13]. Smith and colleagues examined dif-
ferent intervals for the development of PID following a
chlamydia infection using a Markov model [22]. They
used data from a prospective cohort study of women at
high risk of PID [23,24]. Our study addresses thesuggestion of Smith et al. to investigate PID develop-
ment time in women at low risk of chlamydia comparing
data about PID rates from different screening strategies.
Our findings also support those of Smith et al., with the
most cases of PID averted with the longest development
time. Our study estimated that 8-10% of women with
chlamydia infection develop PID, which corresponds to
the estimate of Adams and colleagues, based on data
about clinical PID reports from primary care [25], but
lower than the estimated progression fraction assumed
in many cost-effectiveness studies [13]. The baseline
value of 30% (7/23) for the proportion of PID cases due
to chlamydia infection in the trial is in line with what
has been reported in the literature [2,3].
A constant rate of progression from chlamydia to clin-
ically diagnosed PID or progression at the end of the
course of chlamydia was compatible with the findings of
the Prevention of Pelvic Infection trial. The two scenar-
ios differ conceptually, however, regarding the window
of opportunity for screening to prevent PID. In the sce-
nario with progression at the end of infection, the time
window for preventing PID is the whole infection period.
In the constant progression scenario, the time window
might be shorter than the duration of infection. The
constant rate assumes that the time between start of in-
fection and developing PID follows an exponential distri-
bution. This implies that some women will develop PID
soon after infection whereas others will develop it very
late in their infection. In practice, there would always be
some unpreventable chlamydial PID as the screening
interval cannot be made short enough to find each
infected woman before she progresses. Progression at
the end of the course of chlamydia infection is probably
less biologically plausible than constant progression.
Progression early in the course of chlamydia infection,
represented in the model as immediate progression, was
the least likely. This differs from the findings from ani-
mal models in which progression in the mouse model
happens by 24 hours [12] and in the guinea pig model
within the first week [26]. It is possible that C. tracho-
matis ascends early in the course of infection in humans
but that clinical PID is observed later. However, if most
chlamydia infections in women progressed so early in
the course of infection, many clinical PID cases would
be expected to have occurred before detection of preva-
lent infections through screening [27]. The development
of PID symptoms and clinical diagnosis have to be able
to happen over a longer time course for screening to
achieve reductions in the incidence of PID of 35% [11]
or more [9,10], given that only 30% of PID cases are
caused by chlamydia and that PID resulting from a new
infection during the follow-up period cannot be pre-
vented [28]. Most women with PID in the trial reported
sexual intercourse with two or more partners during the
Herzog et al. BMC Infectious Diseases 2012, 12:187 Page 8 of 9
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ascending C. trachomatis infection [23], it could be
hypothesised that sex with a new partner alters the com-
position of vaginal flora and encourages progression of
prevalent endocervical chlamydia to PID.
This study has implications for future research and
practice. The relatively low estimated fraction of
asymptomatic chlamydia progressing to clinical PID
can be used to give advice to women with chlamydia
infection. The uptake of the screening interventions in
randomised controlled trials was much higher than up-
take rates observed in practice [29,30]. We plan to con-
duct future modelling studies that investigate the
impact of achievable levels of chlamydia screening on
the interruption of ascending chlamydia infections
using a model that can also examine the effect of dif-
ferences in the timing of progression. The numbers of
PID cases prevented could then be compared to those
prevented indirectly as the result of reduced exposure
to chlamydia. The findings of this study suggest that
clinical PID can occur throughout the course of a chla-
mydia infection, which leaves a window of opportunity
for screening to prevent PID.Additional file
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